bioAffinity Technologies, Inc.(BIAF)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $9.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BIAF Stock Analysis & AI Quality Score
AI stock analysis and institutional research for bioAffinity Technologies, Inc. (BIAF), a Healthcare sector company. BIAF is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $9.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), bioAffinity Technologies, Inc. reports quarterly revenue of $1.4M, net income of $-3.6M, free cash flow of $-3.2M. Top institutional holders of BIAF by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, J. Safra Sarasin Holding AG, based on the most recent SEC filings. BIAF trades on the Nasdaq exchange and files with the SEC under CIK 1712762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIAF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for bioAffinity Technologies, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$1.4M
Net Income
Q1 2026
$-3.6M
Free Cash Flow
Q1 2026
$-3.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-22.0% YoYNet Income
-87.9% YoYOperating Income
-32.6% YoYEPS (Diluted)
-851.6% YoYTotal Assets
+33.3% YoYOp. Cash Flow
-54.5% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $6.2M -22.0% | $7.9M +14.5% | $6.9M | — |
| Net Income | $-14.9M -87.9% | $-7.9M +2.7% | $-8.2M -28.9% | $-6.3M |
| Operating Income | $-10.6M -32.6% | $-8.0M -98.8% | $-4.0M -81.8% | $-2.2M |
| EPS (Diluted) | $-8.66 -851.6% | $-0.91 +49.7% | $-1.81 | — |
| Total Assets | $11.0M +33.3% | $8.2M -32.5% | $12.2M +738.2% | $1.5M |
| Operating Cash Flow | $-9.3M -54.5% | $-6.0M -48.3% | $-4.1M -98.7% | $-2.0M |
Get alerted when BIAF's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for bioAffinity Technologies, Inc. including:
Top Institutional Holders of BIAF
VANGUARD CAPITAL MANAGEMENT LLC
$212.7K55,543 shGEODE CAPITAL MANAGEMENT, LLC
$185.0K48,293 shJ. Safra Sarasin Holding AG
$164.0K42,600 shVANGUARD FIDUCIARY TRUST CO
$119.0K31,071 shSchonfeld Strategic Advisors LLC
$93.5K24,413 shSTATE STREET CORP
$55.1K14,386 shNORTHERN TRUST CORP
$48.7K12,725 shUBS Group AG
$35.3K9,214 shTower Research Capital LLC (TRC)
$7.9K2,063 shAmeritas Advisory Services, LLC
$3.8K1,000 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $212.7K | 55,543 |
| GEODE CAPITAL MANAGEMENT, LLC | $185.0K | 48,293 |
| J. Safra Sarasin Holding AG | $164.0K | 42,600 |
| VANGUARD FIDUCIARY TRUST CO | $119.0K | 31,071 |
| Schonfeld Strategic Advisors LLC | $93.5K | 24,413 |
| STATE STREET CORP | $55.1K | 14,386 |
| NORTHERN TRUST CORP | $48.7K | 12,725 |
| UBS Group AG | $35.3K | 9,214 |
| Tower Research Capital LLC (TRC) | $7.9K | 2,063 |
| Ameritas Advisory Services, LLC | $3.8K | 1,000 |
More Healthcare Companies
View all Healthcare →Put BIAF on your watchlist
Track score changes the day bioAffinity Technologies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BIAF a good stock to buy?
13F Pro's AI-powered analysis of bioAffinity Technologies, Inc. (BIAF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIAF are available on the BIAF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BIAF?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIAF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of bioAffinity Technologies, Inc.'s investment landscape.